These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19768353)

  • 1. Enhancing the delivery of erythropoietin and its variants into the ischemic brain.
    Hermann DM
    ScientificWorldJournal; 2009 Sep; 9():967-9. PubMed ID: 19768353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.
    Garcia-Rodriguez JC; Sosa-Teste I
    ScientificWorldJournal; 2009 Sep; 9():970-81. PubMed ID: 19768354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies.
    Hermann DM
    ScientificWorldJournal; 2010 Nov; 10():2285-7. PubMed ID: 21103797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different expression patterns of Ngb and EPOR in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of Neuro-EPO for ischemic insults to the gerbil brain.
    Gao Y; Mengana Y; Cruz YR; Muñoz A; Testé IS; García JD; Wu Y; Rodríguez JC; Zhang C
    J Histochem Cytochem; 2011 Feb; 59(2):214-27. PubMed ID: 21339183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal neuro EPO could be a reliable choice for neuroprotective stroke treatment.
    Parra AL; Rodriguez JC
    Cent Nerv Syst Agents Med Chem; 2012 Mar; 12(1):60-8. PubMed ID: 22376076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.
    Wang Y; Zhang ZG; Rhodes K; Renzi M; Zhang RL; Kapke A; Lu M; Pool C; Heavner G; Chopp M
    Br J Pharmacol; 2007 Aug; 151(8):1377-84. PubMed ID: 17603558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A neuroprotective derivative of erythropoietin that is not erythropoietic.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Nov; 13(11):1517-9. PubMed ID: 15500399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental evidence of the potential use of erythropoietin by intranasal administration as a neuroprotective agent in cerebral hypoxia.
    Merelli A; Caltana L; Lazarowski A; Brusco A
    Drug Metabol Drug Interact; 2011; 26(2):65-9. PubMed ID: 21756166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia.
    Rodríguez Cruz Y; Mengana Támos Y; Muñoz Cernuda A; Subirós Martines N; González-Quevedo A; Sosa Testé I; García Rodríguez JC
    ScientificWorldJournal; 2010 Nov; 10():2288-300. PubMed ID: 21103798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin.
    Mahmood A; Lu D; Qu C; Goussev A; Zhang ZG; Lu C; Chopp M
    J Neurosurg; 2007 Aug; 107(2):392-7. PubMed ID: 17695395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
    Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
    Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
    Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
    Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin in the treatment of acute ischemic stroke.
    Ehrenreich H; Weissenborn K; Prange H; Schneider D; Weimar C; Wartenberg K; Schellinger PD; Bohn M; Becker H; Wegrzyn M; Jähnig P; Herrmann M; Knauth M; Bähr M; Heide W; Wagner A; Schwab S; Reichmann H; Schwendemann G; Dengler R; Kastrup A; Bartels C;
    Stroke; 2009 Dec; 40(12):e647-56. PubMed ID: 19834012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative.
    Grasso G; Sfacteria A; Erbayraktar S; Passalacqua M; Meli F; Gokmen N; Yilmaz O; La Torre D; Buemi M; Iacopino DG; Coleman T; Cerami A; Brines M; Tomasello F
    J Neurosurg Spine; 2006 Apr; 4(4):310-8. PubMed ID: 16619678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!
    Lapchak PA
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1179-86. PubMed ID: 20828227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives.
    Villa P; van Beek J; Larsen AK; Gerwien J; Christensen S; Cerami A; Brines M; Leist M; Ghezzi P; Torup L
    J Cereb Blood Flow Metab; 2007 Mar; 27(3):552-63. PubMed ID: 16835629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sub-acute systemic erythropoietin administration reduces ischemic brain injury in an age-dependent manner.
    Thériault P; Le Béhot A; ElAli A; Rivest S
    Oncotarget; 2016 Jun; 7(24):35552-35561. PubMed ID: 27248662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis.
    Savino C; Pedotti R; Baggi F; Ubiali F; Gallo B; Nava S; Bigini P; Barbera S; Fumagalli E; Mennini T; Vezzani A; Rizzi M; Coleman T; Cerami A; Brines M; Ghezzi P; Bianchi R
    J Neuroimmunol; 2006 Mar; 172(1-2):27-37. PubMed ID: 16337691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lack of CD131 and the inhibition of Neuro-2a growth by carbamylated erythropoietin.
    Ding J; Li QY; Yu JZ; Wang X; Lu CZ; Ma CG; Xiao BG
    Cell Biol Toxicol; 2015 Feb; 31(1):29-38. PubMed ID: 25656842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of erythropoietin and its derivatives to treat spinal cord injury.
    Mofidi A; Bader A; Pavlica S
    Mini Rev Med Chem; 2011 Aug; 11(9):763-70. PubMed ID: 21707531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.